argenx (NASDAQ:ARGX) Rating Increased to Strong-Buy at Baird R W

Baird R W upgraded shares of argenx (NASDAQ:ARGX - Free Report) from a hold rating to a strong-buy rating in a research report report published on Tuesday, May 13th,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 price target on shares of argenx in a research note on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Citigroup reiterated an "outperform" rating on shares of argenx in a research note on Wednesday, May 14th. JMP Securities set a $699.00 price objective on shares of argenx in a research note on Wednesday, May 14th. Finally, William Blair reaffirmed an "outperform" rating on shares of argenx in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $698.11.

argenx Price Performance

NASDAQ:ARGX traded down $1.09 during trading hours on Tuesday, hitting $577.02. The company had a trading volume of 151,595 shares, compared to its average volume of 324,231. argenx has a 52 week low of $356.38 and a 52 week high of $678.21. The company has a market capitalization of $35.23 billion, a PE ratio of -654.79 and a beta of 0.57. The stock has a 50-day moving average price of $591.36 and a 200 day moving average price of $613.42.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million. Analysts anticipate that argenx will post 3.13 EPS for the current fiscal year.

Institutional Trading of argenx

Large investors have recently modified their holdings of the company. FMR LLC grew its stake in shares of argenx by 17.2% during the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after purchasing an additional 824,750 shares during the period. Millennium Management LLC grew its position in argenx by 316.9% during the first quarter. Millennium Management LLC now owns 268,604 shares of the company's stock valued at $158,977,000 after buying an additional 204,180 shares during the period. Point72 Asset Management L.P. purchased a new stake in argenx during the fourth quarter valued at approximately $91,013,000. Allspring Global Investments Holdings LLC raised its position in argenx by 38,152.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock worth $89,391,000 after acquiring an additional 143,834 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of argenx by 53,684.9% during the 1st quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock worth $802,200,000 after acquiring an additional 135,286 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.